Noe­ma Phar­ma rais­es $112M Se­ries B to ad­vance CNS dis­or­der pipeline with Roche can­di­dates

Swiss biotech Noe­ma Phar­ma jump­start­ed back in 2020 with a $60 mil­lion Se­ries A fi­nanc­ing round. To­day, it’s wrap­ping up its Se­ries B round with an­oth­er $112 mil­lion to de­vel­op its pipeline of mol­e­cules fo­cused on cen­tral ner­vous sys­tem dis­or­ders.

Noe­ma start­ed out with four clin­i­cal stage as­sets in-li­censed from Roche. The com­pa­ny says it will use this new round of fi­nanc­ing to push for­ward its lead can­di­date basimglu­rant (NOE-101), an mGluR5 in­hibitor which is cur­rent­ly be­ing eval­u­at­ed in Phase IIb clin­i­cal tri­als for se­vere pain in trigem­i­nal neu­ral­gia and seizures in tuber­ous scle­ro­sis com­plex.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER